Scholarlink

<p>The fungicide metconazole, which acts as a sterol 14α-demethylation inhibitor (DMI), can exhibit strong inhibitory effects on <i>Fusarium pseudograminearum</i>. However, the resistance mechanism as well as the risk that <i>F. pseudograminearum</i> develops resistance to metconazole is yet to be fully assessed. In this study, metconazole displayed a mean EC<sub>50</sub> value of 0.0559&#xa0;μg/mL against 105 <i>F. pseudograminearum</i> isolates. Ten sensitive parental isolates were then subjected to fungicide adaptation to generate resistant mutants, with in vitro experiments subsequently highlighting the inferior fitness of the mutants. In addition, metconazole exhibited positive cross-resistance with both mefentrifluconazole and tebuconazole. Altogether, the results confirmed the low risk that <i>F. pseudograminearum</i> develops resistance to metconazole. Finally, a mutation genotype (M151T) was identified in FpCYP51B, with the mutants also overexpressing the <i>FpCYP51</i> genes. Subsequent molecular docking and transformation-based experiments indicated that M151T substitution and overexpression in <i>FpCYP51</i> genes conferred resistance to metconazole in <i>F. pseudograminearum</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Resistance risk asssement and molecular basis of metconazole in Fusarium pseudograminearum

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月1日

查看全文
  • Guixiang Li,
  • Yiwen Li,
  • Ling Zhang,
  • Han Jiang,
  • Kang Yuan,
  • Jianqiang Miao,
  • Xili Liu

摘要

The fungicide metconazole, which acts as a sterol 14α-demethylation inhibitor (DMI), can exhibit strong inhibitory effects on Fusarium pseudograminearum. However, the resistance mechanism as well as the risk that F. pseudograminearum develops resistance to metconazole is yet to be fully assessed. In this study, metconazole displayed a mean EC50 value of 0.0559 μg/mL against 105 F. pseudograminearum isolates. Ten sensitive parental isolates were then subjected to fungicide adaptation to generate resistant mutants, with in vitro experiments subsequently highlighting the inferior fitness of the mutants. In addition, metconazole exhibited positive cross-resistance with both mefentrifluconazole and tebuconazole. Altogether, the results confirmed the low risk that F. pseudograminearum develops resistance to metconazole. Finally, a mutation genotype (M151T) was identified in FpCYP51B, with the mutants also overexpressing the FpCYP51 genes. Subsequent molecular docking and transformation-based experiments indicated that M151T substitution and overexpression in FpCYP51 genes conferred resistance to metconazole in F. pseudograminearum.